- Home
- NGNE vs SUJA Comparison
NGNE vs SUJA Comparison
Compare NGNE & SUJA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NGNE | SUJA |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.2M | 426.8M |
| IPO Year | 2014 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NGNE | SUJA |
|---|---|---|
| Price | $35.40 | $10.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $63.57 | N/A |
| AVG Volume (30 Days) | 219.9K | ★ 269.6K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $8.71 |
| 52 Week High | $37.27 | $10.78 |
Technical Indicators
Market Signals| Indicator | NGNE | SUJA |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 72.99 |
| Support Level | $19.27 | N/A |
| Resistance Level | $36.37 | N/A |
| Average True Range (ATR) | 2.05 | 0.91 |
| MACD | 0.39 | 0.15 |
| Stochastic Oscillator | 95.22 | 91.34 |
Price Performance
Historical ComparisonAbout NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.